DIH Holdings US Stock Price, News & Analysis

DIH (NASDAQ:DHAI), a provider of advanced robotic rehabilitation devices, has designated Rehazentrum Valens as a DIH Center of Excellence. The Swiss rehabilitation center, established in 1970, specializes in neurological, musculoskeletal, and internal medicine rehabilitation.

Rehazentrum Valens utilizes DIH's comprehensive solution suite, including Erigo®Pro, Lokomat®Pro, Andago®, C-Mill VR+, and the complete Armeo® product family for various rehabilitation needs. The center has been implementing robotic-assisted rehabilitation for over 20 years, starting with one of the first Lokomat systems.

This partnership aims to showcase best practices in rehabilitation robotics and contribute to the development of advanced rehabilitation technologies, while demonstrating how DIH therapy solutions improve patient outcomes.

DIH (NASDAQ:DHAI) reported Q3 FY2025 financial results with revenue of $15.1 million, marking a 21% decline from the previous year. Device revenue fell 26% to $11.7 million, while service revenue grew 4% to $3.1 million. The company experienced significant revenue declines in EMEA (29%) and Americas (7%), primarily due to import restrictions related to the Russia-Ukraine conflict affecting Eastern European sales.

Gross profit decreased 30.4% while operating expenses increased, with SG&A rising 50.6% to $8.2 million. The company closed a public offering raising $4.6 million gross proceeds. Despite challenges, DIH reiterated its FY2025 revenue guidance of $60-67 million and announced new partnerships with Nobis Rehabilitation Partners and Zahrawi Group to expand its distribution network.

DIH (NASDAQ: DHAI) announced the expansion of its strategic partnership with Zahrawi Group to include Saudi Arabia, extending their collaboration that began in 2019. The partnership now covers four countries: UAE, Qatar, Bahrain, and Saudi Arabia.

The expanded collaboration aims to enhance the distribution of DIH's advanced robotic rehabilitation devices across these regions, leveraging Zahrawi Group's established presence in the Gulf Cooperation Council healthcare sector. DIH's technology incorporates visual stimulation for clinical research and functional rehabilitation in patients with walking impairments, reduced balance, and impaired arm and hand functions.

Dr. Patrick Bruno, DIH's Chief Market Officer, emphasized the partnership's focus on making advanced medical technologies more accessible to healthcare providers across the four countries. Abdulrahman Ramadan, Zahrawi Group's CEO, confirmed the alignment with their mission to provide innovative healthcare solutions.

DIH Holding US (NASDAQ: DHAI) has successfully closed its previously announced public offering, raising $4.6 million in gross proceeds. The offering consisted of 5,937,100 units priced at $0.7832 per unit, with each unit comprising one share of Class A common stock and one Class A warrant. The warrants are immediately exercisable at $0.7832 per share and will expire after five years.

Maxim Group served as the sole placement agent for the offering. The company plans to utilize the net proceeds for capital expenditures, working capital, and general corporate purposes. The offering was conducted pursuant to a registration statement on Form S-1 that was declared effective by the SEC on January 31, 2025.

DIH (NASDAQ: DHAI), a provider of advanced robotic rehabilitation devices, has announced the pricing of a $4.6 million public offering. The offering consists of 5,937,100 units priced at $0.7832 per unit. Each unit includes one share of Class A common stock (or pre-funded warrant) and one Class A warrant.

The Class A warrants will have an exercise price of $0.7832 per share, will be immediately exercisable, and will expire after five years. The offering is expected to close around February 3, 2025. Maxim Group is serving as the sole placement agent.

The company plans to use the net proceeds for capital expenditures, working capital, and general corporate purposes. The offering is being made pursuant to an effective registration statement on Form S-1.

DIH (NASDAQ:DHAI) has announced a strategic partnership with Nobis Rehabilitation Partners to integrate Andago®, an overground gait and balance training device, into all of Nobis' newly established hospitals. Nobis, founded in 2018, currently manages over 17 inpatient rehabilitation hospitals across the US, with more in development.

The partnership aims to enhance rehabilitation services by implementing advanced technology that ensures both patient and staff safety. Andago® provides intelligent dynamic body weight support for walking and standing practice, particularly beneficial for patients with stroke, spinal cord injury, brain injury, and other neurologic and orthopedic conditions.

This collaboration combines DIH's technological expertise with Nobis' clinical experience to improve care quality and expand treatment accessibility. The integration of Andago® devices aligns with both companies' goals of advancing rehabilitation therapy standards and delivering quality-driven results.

DIH (NASDAQ:DHAI) has appointed Shepherd Center as a DIH Center of Excellence, establishing a strategic partnership to enhance rehabilitation outcomes. Shepherd Center, located in Atlanta, Georgia, specializes in neurorehabilitation and utilizes DIH's advanced robotic devices including Erigo®Pro, Lokomat®Pro, C-Mill VR+, and the Armeo® product family.

The partnership aims to showcase best practices in rehabilitation robotics and contribute to the development of advanced rehabilitation technologies. Shepherd Center's expertise focuses on complex conditions including spinal cord and brain injuries, multi-trauma, traumatic amputations, stroke, multiple sclerosis, and pain.

DIH (NASDAQ:DHAI) has designated Sheltering Arms Institute, a collaboration with VCU Health, as a DIH Center of Excellence. The institute, located in Richmond, Virginia, utilizes DIH's Total Solution, including Erigo®Pro, Lokomat®Pro, Andago V2.0®, RYSEN, C-Mill VR+, Armeo®Power, and Armeo®Spring to provide personalized rehabilitation care. This partnership strengthens DIH's presence among top-tier healthcare providers and recognizes Sheltering Arms Institute's role in showcasing best practices in rehabilitation robotics. The institute will contribute to developing advanced rehabilitation technologies and implementing them across North America.

DIH (NASDAQ:DHAI) reported Q2 2025 financial results with revenue of $18.2 million, up 39% year-over-year. Device revenue grew 49% to $15.0 million, while service revenue remained flat at $2.7 million. The company saw significant growth in EMEA (72%) and Americas (20%). Gross margin improved to 52.6%, and income before taxes reached $0.1 million.

The company restated Q1 2025 revenue to $17.0 million (30% YoY growth) from previously reported $16.2 million. DIH revised its fiscal year 2025 revenue guidance to $60-67 million. The restatement was due to timing adjustments for two device sales in June 2024.